In:
Journal of Comparative Effectiveness Research, Becaris Publishing Limited, Vol. 8, No. 13 ( 2019-10), p. 1111-1123
Abstract:
Aim: Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs). Patients & methods: This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims – US Database. Results: Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs.
Type of Medium:
Online Resource
ISSN:
2042-6305
,
2042-6313
DOI:
10.2217/cer-2019-0091
Language:
English
Publisher:
Becaris Publishing Limited
Publication Date:
2019
detail.hit.zdb_id:
2669725-7
Permalink